Argos Therapeutics Inc.: Argos Therapeutics to Hold First Quarter 2015 Financial Results Conference Call on Thursday, May 14, 2015

Tickers: ARGS
DURHAM, N.C., May 7, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its ArcelisĀ® technology platform, today announced that the Company's first quarter 2015 financial results will be released after market close on Thursday, May 14, 2015. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.

To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 42530313. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.argostherapeutics.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its ArcelisĀ® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a separate ArcelisĀ®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients.www.argostherapeutics.com.

CONTACT: Media:

         Adam Daley

         Berry & Company Public Relations

         adaley@berrypr.com

         (212) 253-8881

         

         Investors:

         Carol Werther

         Burns McClellan

         cwerther@burnsmc.com

         (212) 213-0006


distributed by

This content was issued by Argos Therapeutics Inc. on the 2015-05-07 and was initially posted on www.argostherapeutics.com. It was distributed, unedited and unaltered, by noodls on 2015-05-07 20:40:52 UTC. The original issuer is solely responsible for the accuracy of the information contained therein.